Review of the REPRISE Trial: Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Journal Title: Nephrology – Open Journal - Year 2018, Vol 4, Issue 1
Abstract
In the past, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and its Outcomes (TEMPO) trial showed Tolvaptan, a vasopressin V2-receptor antagonist, slowed the decline in the estimated Glomerular Filtration Rate (eGFR) in patients with estimated creatinine clearance of ≥60 ml per minute. With this in consideration, Replicating Evidence of Preserved Renal Function: Investigation of Tolvaptan Safety and Efficacy (REPRISE) trial was conducted to assess the efficacy and safety of Tolvaptan in patients with later stage ADPKD. In this trial, 1370 patients with later-stage ADPKD were randomized. These patients were either 18 to 55-years-old with eGFR of 25 to 65 mL per minute per 1.73 m2 of body surface area or 56 to 65-years-old with eGFR of 25 to 44 mL per minute per 1.73 m2 . The primary end-point of this trial was the change in eGFR between baseline and end of trial period, with adjustments made for exact duration that each patient participated for, interpolated to 1 year. The change from baseline that was noted in the Tolvaptan group was -2.34 mL per minute per 1.73 m2 vs. -3.61 mL per minute per 1.73 m2 in the placebo group. A difference of 1.27 mL per minute per 1.73 m2 (95% CI, p less than 0.001) was noted. Based on the data collected by the REPRISE trial over a 1-year period, it can be concluded that Tolvaptan slows the decline in eGFR than placebo in patients with later stage ADPKD.
Authors and Affiliations
Soroush Nomigolzar, Himax Patel
Keywords
Related Articles
- EP ID EP558760
- DOI 10.17140/NPOJ-4-119
- Views 153
- Downloads 0
A New Hypothesis: The Immunomodulatory Effects of Mesenchymal Stromal Cell Derived Extracellular Vesicles in Ischemic Kidney Injury Partly through Spleen
Ischemic Reperfusion Injury (IRI) is a major reason for Acute Kidney Injury (AKI) in hospitalization patients and could continue to result in end-stage kidney fibrosis. Mesenchymal Stromal Cells (MSCs) are regarded as a...
Fibroblast Growth Factor 23 as a Therapeutic Target
This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibr...
Recent Advances in Fibro-blast Growth Factor-23 Functions
During the past decade a lot of work has been done to better understand the roles of fibroblast growth factor-23 (FGF-23); a relatively newly discovered endocrine hormone, in multiple organ systems in the body. This revi...
What we do and do not know About Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Woman’s Day
Chronic Kidney Disease affects approximately 10% of the world’s adult population: it is within the top 20 causes of death worldwide, and it’s impact on patients and their families can be devastating. World Kidney Day and...
Effect of Diethylenetriaminepentaacetic Acid (DTPA) on Crystal Growth and Morphology of Calcium Oxalate
Introduction: One of the most common and painful diseases observed in the tropical regions is kidney stone formation. This can be due to various factors such as the amount of water consumption, climatic conditions, lifes...